
Fig. 1



	R_1	R_2	R_3	R_4
α-amanitin	OH	OH	NH_2	OH
β-amanitin	OH	OH	OH	OH
γ-amanitin	H	OH	NH_2	OH
ε-amanitin	H	OH	OH	OH
amanin	OH	OH	OH	H
amaninamide	OH	OH	NH_2	H
amanullin	H	H	NH_2	OH
amanullinic acid	H	H	OH	OH

Fig. 2



SKOV-3 cells
BrdU assay
72h incubation time
Viability [%]
Concentration [M]
Herceptin
α-Amanitin
Her-DSC-30.0134
Her-DCC-30.0252
Her-DSC-30.0256
Her-DCC-30.0127

Fig. 3



SK-BR-3 cells
BrdU assay
72h incubation time
Viability [%]
Concentration [M]
Herceptin
α-Amanitin
Her-DSC-30.0134
Her-DCC-30.0252
Her-DSC-30.0256
Her-DCC-30.0127

Fig. 4



NCI-N87 cells
BrdU assay
72h incubation time
Viability [%]
Concentration [M]
Herceptin
α-Amanitin
Her-DSC-30.0134
Her-DCC-30.0252
Her-DSC-30.0256
Her-DCC-30.0127

Fig. 5



MDA-MB231 cells
BrdU assay
72h incubation time
Viability [%]
Concentration [M]
Herceptin
α-Amanitin
Her-DSC-30.0134
Her-DCC-30.0252
Her-DSC-30.0256
Her-DCC-30.0127

Fig. 6



16,0
14,0
12,0
10,0
8,0
6,0
4,0
2,0
0,0
released amanitin (%)
Herceptin-Ester-30.0001
Herceptin-DCC-30.0252
Herceptin-DSC-30.0134
0
1
2
3
4
7
9
11
14
plasma incubation time [days]

Fig. 7



1,2
1,0
0,8
0,6
0,4
0,2
0,0
released amanitin (%)
Herceptin-DCC-30.0252
Herceptin-DSC-30.0134
0
1
2
3
4
7
9
11
14
plasma incubation time [days]

Fig. 8




SKOV-3 cells
BrdU-assay before/after plasma incubation
Viability [%]
110
100
90
80
70
60
50
40
30
20
10
0
10-12
10-11
10-10
10-9
10-8
10-7
10-6
10-5
Concentration [M]
Her-DSC-30.0134 before plasma incubation
Her-DSC-30.0134 11 days plasma incubation
Her-DCC-30.0252 before plasma incubation
Her-DCC-30.0252 11 days plasma incubation

Fig. 9


SKOV-3 xenograft
50µg/kg - 1x i.v. day 19
Tumore volume [mm3]
2500
2250
2000
1750
1500
1250
1000
750
500
250
0
10
15
20
25
30
35
40
45
50
55
60
65
70
Time [days]
1x i.v.
50µg/kg
Negative control
Herceptin
Her-DSC-30.0134
Her-DCC-30.0252